Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support
Montefiore Medical Center
50 participants
Mar 12, 2025
INTERVENTIONAL
Conditions
Summary
Contemporary left ventricular assist device (LVAD) therapy improves survival during advanced heart failure but vascular aging develops rapidly leading to major adverse events including stroke and bleeding in nearly half of patients. In this study, the study team aims to investigate whether sildenafil pharmacotherapy, which has anti-fibrotic effects, can reduce vascular aging during LVAD support. An aim of this study is to compare changes in small blood vessels in the gastrointestinal tract between participants receiving sildenafil or placebo. Video capsule endoscopy (VCE) will be used to assess these changes in small blood vessels.
Eligibility
Inclusion Criteria3
- Over 18 years of age
- Supported by a durable LVAD or planned to undergo placement of a durable LVAD
- Be able to give informed consent
Exclusion Criteria4
- History of pre-existing aortic valve prosthesis or an aortic graft
- Allergy to sildenafil
- Taking any nitric oxide (NO) donor medications
- History of complete carotid occlusion
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Orally administered phosphodiesterase-5 (PDE-5) inhibitor, which enhances nitric oxide signaling in platelets and blood vessels.
Matched capsule not containing any medication
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06510322